Aprio Wealth Management LLC Has $777,000 Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Aprio Wealth Management LLC increased its stake in Thermo Fisher Scientific by 52.7%, bringing its total holdings to 1,561 shares valued at $777,000.
• The company's stock has a current market cap of $182.79 billion with a recent P/E ratio of 28.00, and it reported a quarterly EPS of $5.36, exceeding expectations.
• Thermo Fisher Scientific announced a dividend of $0.43 per share, set to be paid on October 15th, which reflects an annualized yield of 0.4%.

Aprio Wealth Management LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 52.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,561 shares of the medical research company's stock after buying an additional 539 shares during the quarter. Aprio Wealth Management LLC's holdings in Thermo Fisher Scientific were worth $777,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in TMO. GAMMA Investing LLC raised its stake in Thermo Fisher Scientific by 60,610.9% during the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after buying an additional 2,415,346 shares during the period. Nuveen LLC acquired a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at about $532,360,000. Farallon Capital Management LLC raised its stake in shares of Thermo Fisher Scientific by 73.8% in the 4th quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock valued at $641,577,000 after purchasing an additional 523,800 shares during the period. Sarasin & Partners LLP acquired a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at about $242,991,000. Finally, Two Sigma Advisers LP raised its stake in shares of Thermo Fisher Scientific by 81.6% in the 4th quarter. Two Sigma Advisers LP now owns 933,200 shares of the medical research company's stock valued at $485,479,000 after purchasing an additional 419,200 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded up $2.71 during midday trading on Friday, reaching $492.20. 1,442,575 shares of the company's stock were exchanged, compared to its average volume of 1,624,930. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market cap of $185.86 billion, a price-to-earnings ratio of 28.47, a P/E/G ratio of 2.63 and a beta of 0.75. The stock's 50-day simple moving average is $460.72 and its 200 day simple moving average is $452.89.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter last year, the company posted $5.37 earnings per share. Thermo Fisher Scientific's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Analyst Ratings Changes

Several research firms have issued reports on TMO. HSBC reissued a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a report on Friday, July 11th. Evercore ISI decreased their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Finally, William Blair began coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating for the company. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $589.38.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,666 shares of company stock worth $13,982,763 over the last three months. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.